Pakistan · Delayed Price · Currency is PKR Liven Pharma Statistics
Total Valuation
Liven Pharma has a market cap or net worth of PKR 3.56 billion. The enterprise value is 3.41 billion.
| Market Cap | 3.56B |
| Enterprise Value | 3.41B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Liven Pharma has 113.04 million shares outstanding. The number of shares has increased by 14.50% in one year.
| Current Share Class | 113.04M |
| Shares Outstanding | 113.04M |
| Shares Change (YoY) | +14.50% |
| Shares Change (QoQ) | -30.41% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.13% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.97 |
| PB Ratio | 3.64 |
| P/TBV Ratio | 3.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 343.22 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 30.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.58 |
| Quick Ratio | 1.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -25.60 |
Financial Efficiency
Return on equity (ROE) is -1.06% and return on invested capital (ROIC) is -7.38%.
| Return on Equity (ROE) | -1.06% |
| Return on Assets (ROA) | -3.83% |
| Return on Invested Capital (ROIC) | -7.38% |
| Return on Capital Employed (ROCE) | -5.64% |
| Weighted Average Cost of Capital (WACC) | 3.99% |
| Revenue Per Employee | 2.85M |
| Profits Per Employee | -214,173 |
| Employee Count | 39 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 1.22 |
Taxes
| Income Tax | -36.12M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.10% in the last 52 weeks. The beta is -0.05, so Liven Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.05 |
| 52-Week Price Change | -49.10% |
| 50-Day Moving Average | 31.34 |
| 200-Day Moving Average | 36.76 |
| Relative Strength Index (RSI) | 51.97 |
| Average Volume (20 Days) | 97,376 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Liven Pharma had revenue of PKR 111.28 million and -8.35 million in losses. Loss per share was -0.08.
| Revenue | 111.28M |
| Gross Profit | -17.23M |
| Operating Income | -61.72M |
| Pretax Income | -44.48M |
| Net Income | -8.35M |
| EBITDA | -29.19M |
| EBIT | -61.72M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 176.79 million in cash and 33.10 million in debt, with a net cash position of 143.69 million or 1.27 per share.
| Cash & Cash Equivalents | 176.79M |
| Total Debt | 33.10M |
| Net Cash | 143.69M |
| Net Cash Per Share | 1.27 |
| Equity (Book Value) | 978.09M |
| Book Value Per Share | 9.29 |
| Working Capital | 181.68M |
Cash Flow
In the last 12 months, operating cash flow was 10.36 million and capital expenditures -29.44 million, giving a free cash flow of -19.08 million.
| Operating Cash Flow | 10.36M |
| Capital Expenditures | -29.44M |
| Depreciation & Amortization | 32.53M |
| Net Borrowing | -7.65M |
| Free Cash Flow | -19.08M |
| FCF Per Share | -0.17 |
Margins
Gross margin is -15.48%, with operating and profit margins of -55.46% and -7.51%.
| Gross Margin | -15.48% |
| Operating Margin | -55.46% |
| Pretax Margin | -39.97% |
| Profit Margin | -7.51% |
| EBITDA Margin | -26.23% |
| EBIT Margin | -55.46% |
| FCF Margin | n/a |
Dividends & Yields
Liven Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.50% |
| Shareholder Yield | -14.50% |
| Earnings Yield | -0.24% |
| FCF Yield | -0.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |